A novel seizure quality index based on ictal parameters for optimizing clinical decision-making in electroconvulsive therapy. Part 2: Validation

  • Laura KranasterEmail author
  • Christine Jennen-Steinmetz
  • Alexander Sartorius
Original Paper


Early identification of patients who are at a high risk for an unfavorable outcome to ECT during the treatment course might be beneficial because it provides an opportunity for timely intensification or optimization of stimulus conditions. We aimed to validate a previously developed seizure quality index (SQI) that delivers a clinically relevant outcome prediction early in the treatment course and can be used within common clinical setting. Therefore, a prospective study was conducted. Patients (n = 26) below the age of 65 years with a depressive episode and the clinical decision for ECT (right unilateral, brief pulse) were included and several ictal parameters, the SQI for non-response and non-remission, and the clinical outcome of the patients were documented. Logistic regression analysis revealed a statistically significant association between the SQI and non-response (p = 0.035). A significant association between the clinical outcome of non-response and the classified outcome of non-response was detected (p = 0.041). The overall classification accuracy regarding response/non-response was 71.3%, and the model revealed a sensitivity of 84.6% and a specificity of 61.5% for non-response. In this study, we could validate the SQI for the clinical outcome of non-response, but not for non-remission. Based on our data, the SQI might become an interesting clinical tool for early outcome prediction for ECT in patients with depression.


Electroconvulsive therapy Depression Outcome Prediction 



LK received support by the German Research Foundation (DFG—Grant no. KR 4689/3-1).

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.


  1. 1.
    Abrams R (2002) Electroconvulsive therapy. Oxford University Press, OxfordGoogle Scholar
  2. 2.
    American Psychiatric Association (2001) The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging (a task force report of the American Psychiatric Association). American Psychiatric Association, Washington, DCGoogle Scholar
  3. 3.
    Bauer M, Tharmanathan P, Volz HP, Moeller HJ, Freemantle N (2009) The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci 259:172–185CrossRefGoogle Scholar
  4. 4.
    Fink M (2009) Electroconvulsive therapy—a guide for professionals and their patients. Oxford University Press, New YorkGoogle Scholar
  5. 5.
    Fink M (2014) What was learned: studies by the consortium for research in ECT (core) 1997–2011. Acta Psychiatr Scand 129:417–426CrossRefGoogle Scholar
  6. 6.
    Folkerts H (1996) The ictal electroencephalogram as a marker for the efficacy of electroconvulsive therapy. Eur Arch Psychiatry Clin Neurosci 246:155–164CrossRefGoogle Scholar
  7. 7.
    Ghaleiha A, Davari H, Jahangard L, Haghighi M, Ahmadpanah M, Seifrabie MA, Bajoghli H, Holsboer-Trachsler E, Brand S (2016) Adjuvant thiamine improved standard treatment in patients with major depressive disorder: results from a randomized, double-blind, and placebo-controlled clinical trial. Eur Arch Psychiatry Clin Neurosci 266:695–702CrossRefGoogle Scholar
  8. 8.
    Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ (2012) Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 69:572–579Google Scholar
  9. 9.
    Haq AU, Sitzmann AF, Goldman ML, Maixner DF, Mickey BJ (2015) Response of depression to electroconvulsive therapy: a meta-analysis of clinical predictors. J Clin Psychiatry 76:1374–1384CrossRefGoogle Scholar
  10. 10.
    Hoyer C, Kranaster L, Janke C, Sartorius A (2014) Impact of the anesthetic agents ketamine, etomidate, thiopental, and propofol on seizure parameters and seizure quality in electroconvulsive therapy: a retrospective study. Eur Arch Psychiatry Clin Neurosci 264:255–261CrossRefGoogle Scholar
  11. 11.
    Kranaster L, Aksay SS, Bumb JM, Hoyer C, Jennen-Steinmetz C, Sartorius A (2018) A novel seizure quality index based on ictal parameters for optimizing clinical decision making in electroconvulsive therapy. Part 1: development. Eur Arch Psychiatry Clin Neurosci 268:819–830CrossRefGoogle Scholar
  12. 12.
    Krystal AD (1998) The clinical utility of ictal eeg seizure adequacy models. Psychiatr Ann 28:30–35CrossRefGoogle Scholar
  13. 13.
    Krystal AD, Weiner RD, Coffey CE (1995) The ictal eeg as a marker of adequate stimulus intensity with unilateral ECT. J Neuropsychiatry Clin Neurosci 7:295–303CrossRefGoogle Scholar
  14. 14.
    Krystal AD, Weiner RD, McCall WV, Shelp FE, Arias R, Smith P (1993) The effects of ECT stimulus dose and electrode placement on the ictal electroencephalogram: an intraindividual crossover study. Biol Psychiatry 34:759–767CrossRefGoogle Scholar
  15. 15.
    Loo C, Simpson B, MacPherson R (2010) Augmentation strategies in electroconvulsive therapy. J ECT 26:202–207CrossRefGoogle Scholar
  16. 16.
    Loo CK, Kaill A, Paton P, Simpson B (2009) The difficult-to-treat electroconvulsive therapy patient - strategies for augmenting outcomes. J Affect Disord 124:219–227CrossRefGoogle Scholar
  17. 17.
    Mankad MV, Beyer JL, Weiner RD, Krystal AD (2010) Clinical manual of electroconvulsive therapy. American Psychiatric Publishing, Washington, DCGoogle Scholar
  18. 18.
    McCall WV (2014) Is remission a necessary and sufficient definition of success in ECT? Part 2. J ECT 30:257–258CrossRefGoogle Scholar
  19. 19.
    McCall WV (2013) Is remission a necessary and sufficient definition of success in electroconvulsive therapy? Part 1. J ECT 29:257Google Scholar
  20. 20.
    Minelli A, Abate M, Zampieri E, Gainelli G, Trabucchi L, Segala M, Sartori R, Gennarelli M, Conca A, Bortolomasi M (2016) Seizure adequacy markers and the prediction of electroconvulsive therapy response. J ECT 32:88–92CrossRefGoogle Scholar
  21. 21.
    Nobler MS, Sackeim HA, Solomou M, Luber B, Devanand DP, Prudic J (1993) EEG manifestations during ECT: effects of electrode placement and stimulus intensity. Biol Psychiatry 34:321–330CrossRefGoogle Scholar
  22. 22.
    Nordenskjold A, von Knorring L, Engstrom I (2012) Predictors of the short-term responder rate of electroconvulsive therapy in depressive disorders—a population based study. BMC Psychiatry 12:115CrossRefGoogle Scholar
  23. 23.
    Perera TD, Luber B, Nobler MS, Prudic J, Anderson C, Sackeim HA (2004) Seizure expression during electroconvulsive therapy: relationships with clinical outcome and cognitive side effects. Neuropsychopharmacology 29:813–825CrossRefGoogle Scholar
  24. 24.
    Sackeim HA, Prudic J, Devanand DP, Kiersky JE, Fitzsimons L, Moody BJ, McElhiney MC, Coleman EA, Settembrino JM (1993) Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N Engl J Med 328:839–846CrossRefGoogle Scholar
  25. 25.
    Thase ME, Danchenko N, Brignone M, Florea I, Diamand F, Jacobsen PL, Vieta E (2017) Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. Eur Neuropsychopharmacol 27:773–781CrossRefGoogle Scholar
  26. 26.
    Vermeiden M, Kamperman AM, Hoogendijk WJG, van den Broek WW, Birkenhager TK (2017) A randomized clinical trial comparing two two-phase treatment strategies for in-patients with severe depression. Acta Psychiatr Scand 136:118–128CrossRefGoogle Scholar
  27. 27.
    Zimmerman M, Posternak MA, Chelminski I (2004) Implications of using different cut-offs on symptom severity scales to define remission from depression. Int Clin Psychopharmacol 19:215–220CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental HealthHeidelberg UniversityMannheimGermany
  2. 2.Department of Biostatistics, Central Institute of Mental HealthUniversity of HeidelbergMannheimGermany

Personalised recommendations